Business · 1 sources covering this

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·1h ago
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/135d3a094ad201de21dcdc13b1ad25d54cec85e2"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says"></iframe>

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

How 1 sources are covering this

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

More from Business

Walmart Posts Slowest Sales Growth in Years as Americans Tighten Wallets

Dow futures drop 300 points as Treasury yields reverse Bessent-driven decline, Walmart tumbles: Live updates

Walmart hikes full-year outlook, says it will use huge tariff refund to keep prices low

Treasury yields rebound, wiping out the decline following Bessent's intervention

Reader

Trust & legal

Across the network